Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Caitlin Unkenholz, Mateo Mejia Saldarriaga, Esther Ortega, Jorge Monge, Christian A Gordillo, Juan Esteban Velez-Hernandez, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2024-210365

Published: 2024

Journal Articles

Prognostic Factors for Survival in Multiple Myeloma Patients That Receive Bispecific Antibodies: Does Relative Dose Intensity Matters?

Henry Becerra, Emmanuel Bugarin-Estrada, Ruben Niesvizky, Roger Pearse, Jorge Monge, Mateo Mejia Saldarriaga

Blood (2024) 144 (Supplement 1): 1930.

https://doi.org/10.1182/blood-2024-211033

Published: 2024

Journal Articles

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Juan Esteban Velez-Hernandez, Mateo Mejia Saldarriaga, Caitlin Unkenholz, Christian A Gordillo, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Markus Y Mapara, Ruben Niesvizky, Ran Reshef, Samuel Yamshon, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2024-209960

Published: 2024

Journal Articles

CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4 CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Xiangao Huang, David S Jayabalan, Maurizio Di Liberto, Zhengming Chen, Scott Ely, Roger Pearse, Joseph Lane, Gang Lin, Ruben Niesvizky, Selina Chen-Kiang

Blood (2024) 144 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2024-206115

Published: 2024

Journal Articles

Evaluating the Kinetics of Absolute Lymphocyte Counts Following Bispecific T-Cell Engager Therapy to Predict Clinical Outcomes in Relapsed/Refractory Multiple Myeloma

Emmanuel Bugarin-Estrada, Jorge Monge, Roger Pearse, Ruben Niesvizky, Mateo Mejia Saldarriaga

Blood (2024) 144 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2024-209148

Published: 2024

Journal Articles

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Mateo Mejia Saldarriaga, Caitlin Unkenholz, Joshua A Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, Markus Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2023) 142 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2023-187832

Published: 2023

Journal Articles

Young Adults with Multiple Myeloma Have Distinct Clinical and Molecular Characteristics Compared to Older Patients

Mateo Mejia Saldarriaga, Aubrie Sowa, David S Jayabalan, Cara A. Rosenbaum, Roger Pearse, Jorge Monge, Ruben Niesvizky, Mark Bustoros

Blood (2022) 140 (Supplement 1): 9951–9952.

https://doi.org/10.1182/blood-2022-170413

Published: 2022

Journal Articles

Clinical and Genomics Characteristics of Multiple Myeloma with Extramedullary Disease in the Mmrf Registry

Mateo Mejia Saldarriaga, David S Jayabalan, Aubrie Sowa, Jorge Monge, Cara A. Rosenbaum, Roger Pearse, Ruben Niesvizky, Sanjay Patel, Mark Bustoros

Blood (2022) 140 (Supplement 1): 4238–4239.

https://doi.org/10.1182/blood-2022-157191

Published: 2022

Journal Articles

Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Danny Luan, MPH, Paul J Christos, Dr.P.H., M.S., Michael Ancharski, MLS(ASCP), Danielle Guarneri, BS, CCRP, Roger Pearse, MD PhD, Adriana C Rossi, MD MSc, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Adrienne A. Phillips, MD MPH, Jingmei Hsu, MD, Ljiljana V. Vasovic, MD, Yen-Michael S. Hsu, MD PhD, Koen van Besien, MD PhD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140811

Published: 2020

Journal Articles

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Cara A. Rosenbaum, MD, Danny Luan, BS, MPH, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Koen Van Besien, MD PhD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 2026.

https://doi.org/10.1182/blood-2019-127710

Published: 2019

Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2019) 134 (Supplement_1): 4579.

https://doi.org/10.1182/blood-2019-127723

Published: 2019

Journal Articles

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Blood (2019) 134 (Supplement_1): 5644.

https://doi.org/10.1182/blood-2019-130914

Published: 2019

Journal Articles

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

Jorge Monge, MD, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Jin Guo, MD, Jorge Contreras, MD, Kathleen Pogonowski, RN, Natalie Agudo, RN, Danielle Guarneri, BS, CCRP, Brielle Liotta, BS, Eloisi Caldas Lopes, PhD, Roger Pearse, MD PhD, Morton Coleman, MD, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2019) 134 (Supplement_1): 5563.

https://doi.org/10.1182/blood-2019-127697

Published: 2019

Journal Articles

A Phase II Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed By Autologous Stem Cell Transplant for Patients with Multiple Myeloma

Alexandra Gomez-Arteaga, MD, Tomer M Mark, MDMSc, Danielle Guarneri, Paul J Christos, Dr.P.H., M.S., Usama Gergis, MD, June Greenberg, RN, Jingmei Hsu, MD PhD, Sebastian A. Mayer, MD, Ruben Niesvizky, MD, Roger Pearse, MD PhD, Adrienne A. Phillips, MD MPH, Adriana C. Rossi, MDMSc, Morton Coleman, MD, Koen Van Besien, MD PhD, Tsiporah B. Shore, MD

Blood (2017) 130 (Supplement 1): 4546.

https://doi.org/10.1182/blood.V130.Suppl_1.4546.4546

Published: 2017

Journal Articles

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Benjamin Diamond, MD, David S Jayabalan, MSc, Roger Pearse, MD PhD, Art Perry, Karen Pekle, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2017) 130 (Supplement 1): 3102.

https://doi.org/10.1182/blood.V130.Suppl_1.3102.3102

Published: 2017

Journal Articles

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Adriana C Rossi, MD, Ekta Aneja, MBBS, Angelique Boyer, David Jayabalan, BSMS, MSc, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4754.

https://doi.org/10.1182/blood.V124.21.4754.4754

Published: 2014

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Abbe Schickner, BA, John N. Allan, MD, Adriana C Rossi, MD, Roger Pearse, MD PhD, Linda Tegnestam, RN, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pognowski, RN, David Jayabalan, BSMS, MSc, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4761.

https://doi.org/10.1182/blood.V124.21.4761.4761

Published: 2014

Journal Articles

Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50

Joanna Rhodes, MD, Koen van Besien, MD, Hongtao Liu, MDPhD, Usama Gergis, MD, Stephanie B. Tsai, MD MA, Sebastian Mayer, MD, Wendy Stock, MD, Richard A. Larson, MD, Tsiporah B. Shore, MD, Olatoyosi Odenike, MD, Roger Pearse, MD PhD, Lucy A Godley, MD PhD, Tomer M Mark, MD MSc, Justin Kline, MD, Michael R. Bishop, MD, Andrew S. Artz, MD MS

Blood (2014) 124 (21): 1235.

https://doi.org/10.1182/blood.V124.21.1235.1235

Published: 2014

Journal Articles

Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)

Ekta Aneja, MBBS, Adriana C Rossi, MD, Tomer M Mark, MD MSc, David Jayabalan, BSMS, MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Art Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 5778.

https://doi.org/10.1182/blood.V124.21.5778.5778

Published: 2014

Journal Articles

Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF

John N. Allan, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Adriana C Rossi, MD, Linda Tegnestam, RN, Duane C Hassane, PhD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 2452.

https://doi.org/10.1182/blood.V124.21.2452.2452

Published: 2014

NARROW

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Prognostic Factors for Survival in Multiple Myeloma Patients That Receive Bispecific Antibodies: Does Relative Dose Intensity Matters?

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4 CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Evaluating the Kinetics of Absolute Lymphocyte Counts Following Bispecific T-Cell Engager Therapy to Predict Clinical Outcomes in Relapsed/Refractory Multiple Myeloma

Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities

Young Adults with Multiple Myeloma Have Distinct Clinical and Molecular Characteristics Compared to Older Patients

Clinical and Genomics Characteristics of Multiple Myeloma with Extramedullary Disease in the Mmrf Registry

Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

A Phase II Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed By Autologous Stem Cell Transplant for Patients with Multiple Myeloma

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50

Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)

Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only